http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
肺癌組織에서 Carcinoembryonic Antigen의 免疫組織化學的 檢出에 關한 硏究
蘇文永,金仁仙,白承龍 고려대학교 의과대학 1982 고려대 의대 잡지 Vol.19 No.3
The advent of immunohistochemical technique has allowed the more conventional visualization by light microscopy of antigenic cellular constituents. Carcinoembryonic antigen (CEA), which had been thought to be present in colorectal carcinomas only, was later demonstrated in a variety of malignancies as well as nonmalignant diseases. Using formalin-fixed, paraffin-embedded tissues and immunoperoxidase, the author has attempted to demonstrate CEA in 40 lung cancers and 10 nonmalignant diseases. The results obtained are as follows: 1. Seventeen squamous cell carcinomas among 19, three adenocarcinomas among 4 and only 3 of the 12 small cell carcinomas of the lung were positive for CEA. Two mucoepidermoid tumors and one carcinosarcoma were all positive, whereas one carcinoid tumor and one large cell carcinoma were negative for CEA. 2. In the well differentiated squamous cell carcinoma of the lung it was almost exclusively the more keratinized squamous tumor cells that displayed CEA, whereas in the poorly differentiated squamous cell carcinoma and adenocarcinoma the total cell surfaces demonstrated CEA. In mucoepidermoid tumors, the total cell surfaces and the luminal borders of glandular structures were positive for CEA. The stainability of CEA was weak and focal in small cell carcinoma. The stronger staining of CEA was found in the carcinomatous portion of carcinosarcoma. 3. Except two middle lobe syndromes and one tuberculosis of the lung, 2 bronchiectasis, 2 pneumonias and 3 tuberculosis of the lung were positive for CEA, however the staining was weak and mainly found along the luminal border of the bronchiolar epithelial lining cells. In summary, the findings suggested that the immunohistochemical identification of CEA in tissue section processed for routine histopathology was feasible. This might have diagnostic significance to the histopathologist and provide a basis for use of CEA in the follow-up management of patients with lung cancers.